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Sary Despite many new advances in breast cancer therapy since the 1970s, there are only few reports on
improved prognosis in a general population. A foDlow-up of more than 10 years is rarely reported, and a
differentiation according to stage of the disease or between follow-up intervals is seldom made. Our purpose
was to assess whether prognosis of primary breast cancer improved in patients diagnosed between 1970 and
1984 in south-eastern Netherlands, and to distinguish between different stages and follow-up intervals. Data
from 4,467 breast cancer patients diagnosed between 1970 and 1984 were derived from the population-based
Eindhoven Cancer Registry. Follow-up was attained up to 1 July 1991. Relative survival rates, as the ratio of
the observed to the expected rates, were cakulated. In a multivariate analysis a change in prognosis over time
was computed with adjustment for age and stage; this was done separately for 5 year follow-up intervals. The
relative survival rates were 69% after 5 years, 55% after 10 years and 50% after 20 years. Relative survival,
after adjustment for age, was strongly related to the stage of the disease in the first 5 years of follow-up, less
markedly between 5 and 10 years, and to a small, borderline significant, extent after 10 years of follow-up.
Relative survival rates increased markedly over time, during the whole interval of follow-up. This increase was
apparent in all age groups and in all stages, except for those with distant disease at diagnosis. The observed
improvement in survival is unilkely to be explained by the increased use of adjuvant chemo- and hormonal
therapy. Other factors, such as a change in the natural history of the disease in this period, cannot be ruled
out.
In the past 20 years the application of mammography,
cytological examinations and echography has facilitated
earlier diagnosis of breast cancer. Simultaneously, less
mutilating surgery and hormonal and cytotoxic therapy were
introduced. These treatments have proved their efficacy in
academic settings (Early Breast Cancer Trialist's Col-
laborative Group, 1992). Nevertheless, there are only few
reports on improved survival rates in a general population
(Hakulinen et al., 1981; Adami et al., 1986; Levi et al., 1992;
Carstensen et al., 1993; Miller et al., 1993). Moreover,
follow-up of more than 10 years is rare (Adami et al., 1986),
and differentiation according to stage (Hakulinen et al., 1981;
Carstensen et al., 1993; Miller et al., 1993) or between follow-
up intervals is seldom made. We investigated trends in
relative survival rates of breast cancer in women diagnosed
between 1970 and 1984 in south-eastern Netherlands accord-
ing to stage and interval of follow-up.
Subets and method
The study comprised female patients with a first primary
invasive breast cancer diagnosed between 1970 and 1984 in
south-eastern Netherlands, with follow-up until 1991. Data
came from the Eindhoven Cancer Registry, which was
founded in 1955 and has been part of the Comprehensive
Cancer Centre South since 1983 (Coebergh et al., 1992). The
data were derived from the patients' files in the commumity
hospitals, from copies of the pathologists' records and from
the regional Radiotherapy Institute. The registry covered a
densely populated area in south-eastern Netherlands with
about 900,000 inhabitants since 1970. Incidence rates could
be estimated from 1960 onward in this population (Nab et
al., 1993).
In the period 1970-84, 4,549 new breast cancer patients
were registered. Information about the vital status up to 1
July 1991 was obtained from the population administrations.
Of the patient group, 82 women (1.8%) could not be traced,
leaving 4,467 patients for survival analysis. Of this remaining
group, 48 women (1.1%) were lost to follow-up after varying
periods of time.
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Tumour stage at diagnosis was recorded based on the
pathologist's report at surgery and, otherwise, on the basis of
clinical examination. Stage was classified according to the
tumour-node-metastasis (TNM) system of the Union Inter-
nationale Contre le Cancer, version 4, 1987 (Hermanek &
Sobin, 1987).
Relative survival was calculated as the ratio of the
observed actuarial rates to the expected actuarial rates.
Expected survival rates were calculated from life tables for
the regional female population (supplied by The Netherlands
Central Bureau of Statistics), compiled according to 5 year
age groups and year of diagnosis (Hakulinen, 1982).
Actuarial survival curves were computed (Berkson & Gage,
1950) according to age group, tumour stage and period of
diagnosis (1970-74, 1975-79, 1980-84). The excess risk of
death due to breast cancer was modelled using a program of
the Finnish Cancer Registry (Hakulinen & Tenkanen, 1987).
In this model the annual excess mortality is allowed to
depend simultaneously on age, stage and period of diagnosis.
The excess mortality is obtained by taking the difference
between the observed mortality and the expected mortality.
The latter is determined by the age of the patients and the
calendar period. The excess mortality presumably reflects
deaths in which breast cancer is the cause. In this analysis
method it is assumed that the various factors have a propor-
tional effect on the excess death rate. As this assumption
appeared to be violated when the total follow-up interval
after diagnosis was considered, separate analyses were per-
formed for each 5 year interval. In the analyses all variables
were taken to be categorical in the first instance. Because the
factor of primary interest, i.e. diagnostic period, had
estimated effects which were roughly linear with increasing
period, it was introduced in the models using the numerical
codes 0, 1 and 2 for the subsequent periods of diagnosis,
thereby allowing tests for linear trend to be performed. We
investigated whether the diagnostic period effect depended on
stage or age ofpatients at diagnosis by incorporating interac-
tion terms in the models. In the final model death rate ratios
were expressed as the ratio of two death rates in two groups
of patients diagnosed in two consecutive 5 year periods, with
adjustment for age and stage, as an indicator of the change
in prognosis over time. Other statistical methods are
indicated in the text. P-values given are two-sided; 5% was
considered the limit of significance.
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Results
The mean age of the patients in the three periods increased
from 56.7 years in 1970-74 to 59.2 years in 1980-84 (Krus-
kal-Wallis test, P<0.001) (Table I). Of the total patient
group 16% could not be staged because of unknown tumour
size (T) in 31%, unknown nodal status (N) in 16%, unknown
metastatic spread (M) in 13% and a combination of these in
40%. The known TNM stage factors in the patients with
incomplete stage did not suggest a disproportionate presence
ofearly or advanced disease in this group. Among the TNM-
staged patients there was a trend towards a more favourable
stage distribution over time (Xy test for trend, P = 0.003).
Tumour stage correlated with the age at diagnosis: older
patients generally had a more advanced stage at diagnosis (x2
test for trend, P<0.001). Among patients with stages 1-111,
a shift in type of treatment over time was observed from only
surgery towards surgery combined with adjuvant therapy.
Chemotherapy was increasingly administered (Table I).
Observed survival rates at 5, 10 and 20 years were 63%,
44% and 30%, respectively, and the corresponding relative
survival percentages were 69%, 55% and 50%. The 5 year
relative survival rates improved steadily from 61% for
patients diagnosed in 1970-74 to 74% for patients diagnosed
in 1980-84 (P<0.001). The 10 year relative survival rates
increased from 47% to 61% over the same period
(P<0.001). In univariate analysis this increase was apparent
in stages I-III (Figure 1). The 10 year relative survival rate
for stage I was 82%, for stage II 60%, for stage III 33% and
for stage IV 7%. These four survival rates were significantly
different from each other (P<0.001). The group of patients
with distant metastases at diagnosis (stage IV) was analysed
separately in multivariate analysis.
The median survival of patients without distant disease at
diagnosis was 7.5 years. The 5 year relative survival of this
patient group improved steadily, from 63% in 1970-74 to
78% in 1980-84 (P<0.001). Using multivariate analysis the
independent influence of age at diagnosis on relative survival
was small: only for the patient group aged under 40 years in
the first 5 years of follow-up was there a borderline
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significantly worse prognosis. Stage at diagnosis was an
important independent prognostic factor, but its effect
diminished during the follow-up (Table II). Period of diag-
nosis was also a significant and independent prognostic fac-
tor in the first and the second 5 years of follow-up, but not
statistically significant thereafter. The estimated improvement
in relative survival compared with patients diagnosed 5 years
earlier was 30% for the first 5 years offollow-up (P<0.001),
20% in the second 5 years of follow-up (P = 0.02) and 40%
for the third 5 years (P= 0.07). This improvement according
to diagnostic period did not significantly differ between the
three separate stage groups, and was apparent in all age
categories. Among the patients with unknown stage, age-
adjusted relative survival improved by 10% (P>0.1).
Between 1970 and 1984 the 311 patients (7%) with distant
disease at diagnosis had a median observed survival of 1.2
years. Of these patients, 37% survived 2 years, and only 14%
for more than 5 years. Relative survival rates, after adjust-
ment for age, in this group of patients did not change
significantly (Table II).
Discussion
The prognosis of breast cancer patients with non-metastatic
disease diagnosed between 1970 and 1984 in south-eastern
Netherlands improved markedly in all age groups and during
the whole follow-up interval of 15 years. The incmreased sur-
vival rates, together with earlier diagnosis, concur with the
earlier reported marked increase in breast cancer incidence
and stable mortality in this region (Nab et al., 1993).
Explanations for this improvement may include better
therapy, earlier diagnosis and inclusion of less aggressive
cancer types, while the general improvement of life expec-
tancy has been corrected by using relative survival. More
effective treatments include hormonal and cytotoxic therapy,
of which the latter in particular was increasingly admini-
stered as adjuvant, and also as secondary treatment. Cinical
trials (Early Breast Cancer Trialist's Collaborative Group,
1992) have indicated an improved prognosis in patients who
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F-ge 1 The relative survival of breast cancer patients in south-eastern Netherlands diagnosed between 1970 and 1984, according
to stage and period of diagnosis.
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Table I Number (and percentages) of patients with breast cancer according to age. stage and primary
treatment. Data are grouped according to period of diagnosis
1970-74 1975-79 1980-84 Total
No. (%) No. (%) No. (%) No. (%
Age
20-39 years 129 (12) 153 (10) 162 (9) 444 (10)
40-49 years 276 (25) 319 (20) 380 (21) 975 (22)
50-59 years 240 (22) 383 (25) 397 (22) 1020 (23)
60-69 years 271 (24) 366 (24) 385 (22) 1022 (23)
70 + 202 (18) 339 (22) 465 (26) 1006 (22)
Stage
I 161 (14) 275 (18) 374 (21) 810 (18)
II 431 (39) 478 (31) 757 (42) 1666 (37)
III 250 (23) 347 (22) 360 (20) 957 (22)
IV 63 (6) 132 (8) 116 (6) 311 (7)
Unknown 213 (19) 328 (21) 182 (10) 723 (16)
Primary treatment
Surgery 382 (34) 517 (33) 399 (22) 1298 (29)
Surgery + radiotherapy 591 (53) 842 (54) 959 (54) 2392 (54)
Surgery (± radiotherapy) + hormonal therapy 23 (2) 14 (1) 48 (3) 85 (2)
Surgery (± radiotherapy) + chemotherapy 21 (2) 71 (5) 267 (15) 359 (8)
No surgery 101 (9) 116 (7) 116 (6) 333 (7)
Total 1118 (100) 1560 (100) 1789 (100) 4467 (100)
Table H Excess death rate ratios (and 95% confidence intervals) for
each 5 yearfollow-up interval ofpatients with breast cancer, according
to age group, stage and period ofdiagnosis
Follow-up interval
0-5years 5-lOyears 10-15years
(n =3,433) (n =2,273) (n = 1,063)
Age group
20-39 1.3 (1.0-1.7) 1.3 (0.9-1.8) 0.6 (0.2-1.5)
40-49 0.9(0.7-1.1) 1.1 (0.8-1.5) 0.9(0.5-1.7)
50-59a 1 1 1
60-69 0.9 (0.7-1.1) 0.9 (0.7-1.3) 1.5 (0.7-3.0)
70+ 1.1 (0.9-1.4) 1.1 (0.7-1.8) 0.2(0.01-60)
Stage
la 1 1
II 3.4 (2.4-4.9) 1.7 (1.3-2.4) 1.5 (0.7-3.0)
III 9.1 (6.3-13) 3.3 (2.4-4.7) 2.3 (1.0-5.2)
Period of diagnosis
Versus 5 years 0.7 (0.6-0.8) 0.8 (0.7-0.97) 0.6 (0.4-1.1)
earlier diagnosed
Thistablegivestheresults from thefinal model inwhichonlypatients
with stages I-III were included. For patients with unknown stage the
age-adjusted excess death rate ratios (95% CI) according to period of
diagnosis were 0.9 (0.8-1.2), 0.9 (0.7-1.5) and 0.9 (0.3-3.4) for the
three follow-up intervals. For patients with distant disease at diagnosis
the age-adjusted excess death rate ratio (95% CI) was 1.0 (0.9-1.1) for
the first 5 years of follow-up. aReferene category.
received adjuvant chemo- or hormonal therapy. In our series
(besides occasional use in stage I patients) the percentage of
patients with stage II or III disease receiving adjuvant
chemo- or hormonal therapy increased from 2% and 10%,
respectively, in 1970-74 to 22% and 27%, respectively, in
1980-84. However, when multivariate analysis was repeated
while excluding all patients who received adjuvant chemo- or
hormonal therapy, the estimated reductions in excess death
rates thus found were very similar to those shown in Table
II. Therefore, it can be concluded that the increasing use of
these treatment modalities is unlikely to be the cause of the
observed improvement of prognosis.
Although some reports suggest that chemotherapy does
improve survival in advanced breast cancer (A'Hern et al.,
1988), and indeed the percentage of patients with distant
metastases at diagnosis who received chemotherapy increased
from 19% in 1970-74 to 56% in 1980-84, a change in
prognosis in this group could not be determined.
Prevention of complications and better treatment of co-
morbidity may have had a favourable impact on survival
rates. The effect of better radiotherapy (megavoltage therapy
was introduced in 1973) on survival was probably limited
(Fisher et al., 1989; Clark et al., 1992).
The reported overall relative survival rates are similar to
survival rates in some other European cancer registries (Sant
et al.. 1991; Carstensen et al., 1993), but population-based
data on trends in relative survival rates according to stage
are rare. Although such data can demonstrate to what degree
survival rates in cancer patients improved in the general
population, improvements cannot be attributed to specific
causes.
Moreover, some questions remain about the validity of this
considerable improvement in survival rates. Although an
adjustment was made for the increase in earlier stage at
diagnosis over time, using multivariate analysis, earlier detec-
tion may still have had a small impact on stage-specific
outcome, since within the stage groups a trend towards ear-
lier detection is also likely (Black & Welch, 1993). Further-
more, in later years, an increasing number of patients may
have been allocated to higher stages owing to introduction of
more extensive staging procedures, particularly axillary nodal
clearance (Danforth et al., 1986). This may also have con-
tributed to a slightly more favourable outcome in all stages
(Feinstein et al., 1985). As relative survival also improved in
the patients with unknown stage at diagnosis, bias caused by
this group of patients is probably small.
It seems justified to conclude that the improvement in
prognosis in short-term as well as in long-term survival is
real, and is in accordance with the diverging trends in
incidence and mortality in this region. This improvement in
prognosis cannot be attributed to a decrease in other causes
of death. However, detection of less malignant cancer, or a
change in the natural history of the disease in this period,
cannot be ruled out (Joensuu & Toikkanen, 1991).
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